Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ARTV Artiva Biotherapeutics	$2.08 +8.1%	$3.27	$1.78 ▼ $17.31	$50.55M	N/A	175,017 shs	189,129 shs
AVTX Avalo Therapeutics	$4.45 -6.9%	$6.24	$4.15 ▼ $16.00	$47.49M	0.87	53,459 shs	193,145 shs
EQ Equillium	$0.39 +5.8%	$0.56	$0.34 ▼ $1.89	$13.90M	2.06	358,677 shs	51,559 shs
ZIVO ZIVO Bioscience	$16.00 +16.0%	$16.87	$3.13 ▼ $22.15	$61.01M	0.03	963 shs	170 shs

The Best Nuclear Energy Stocks to Buy

Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ARTV Artiva Biotherapeutics	-14.25%	-22.65%	-22.34%	-61.17%	+189,499,900.00%
AVTX Avalo Therapeutics	-5.56%	-5.18%	-18.26%	-43.42%	-64.91%
EQ Equillium	-7.30%	-15.70%	-21.51%	-47.74%	-78.43%
ZIVO ZIVO Bioscience	+16.03%	-14.91%	+1.46%	-20.00%	+102.53%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ARTV Artiva Biotherapeutics	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
AVTX Avalo Therapeutics	3.8425 of 5 stars	4.4	5.0	0.0	0.0	2.1	1.7	1.3
EQ Equillium	2.2438 of 5 stars	3.2	5.0	0.0	0.0	0.6	1.7	0.6
ZIVO ZIVO Bioscience	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ARTV Artiva Biotherapeutics	3.00	Buy	$20.40	883.13% Upside
AVTX Avalo Therapeutics	2.83	Moderate Buy	$33.00	641.57% Upside
EQ Equillium	2.33	Hold	$3.00	671.01% Upside
ZIVO ZIVO Bioscience	2.00	Hold	N/A	N/A

Current Analyst Ratings Breakdown

Latest EQ, ARTV, AVTX, and ZIVO Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
4/8/2025	ARTV Artiva Biotherapeutics	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$23.00 ➝ $23.00
3/28/2025	EQ Equillium	Leerink Partnrs Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
3/28/2025	EQ Equillium	Leerink Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Market Perform	$3.00 ➝ $1.00
3/26/2025	ARTV Artiva Biotherapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$20.00 ➝ $20.00
3/25/2025	ARTV Artiva Biotherapeutics	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$23.00 ➝ $20.00
3/25/2025	ARTV Artiva Biotherapeutics	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$18.00 ➝ $18.00
3/25/2025	ARTV Artiva Biotherapeutics	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$23.00 ➝ $23.00
3/25/2025	AVTX Avalo Therapeutics	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Underperform ➝ Buy	$23.00
3/25/2025	AVTX Avalo Therapeutics	Stifel Nicolaus Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$36.00
3/20/2025	AVTX Avalo Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Neutral ➝ Neutral
3/20/2025	AVTX Avalo Therapeutics	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform	$18.00

(Data available from 5/7/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ARTV Artiva Biotherapeutics	$251K	201.41	N/A	N/A	N/A	∞
AVTX Avalo Therapeutics	$441K	107.69	N/A	N/A	$9.11 per share	0.49
EQ Equillium	$41.10M	0.34	N/A	N/A	$0.64 per share	0.61
ZIVO ZIVO Bioscience	$15.85K	3,849.09	N/A	N/A	($0.81) per share	-19.75

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ARTV Artiva Biotherapeutics	N/A	N/A	0.00	N/A	N/A	N/A	N/A	N/A	6/23/2025 (Estimated)
AVTX Avalo Therapeutics	-$31.54M	N/A	0.00	N/A	N/A	N/A	-442.16%	122.99%	5/12/2025 (Estimated)
EQ Equillium	-$13.34M	-$0.23	N/A	N/A	N/A	-10.05%	-20.68%	-10.77%	5/8/2025 (Estimated)
ZIVO ZIVO Bioscience	-$7.78M	-$4.28	N/A	∞	N/A	N/A	N/A	-2,240.92%	5/12/2025 (Estimated)

Latest EQ, ARTV, AVTX, and ZIVO Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/12/2025	Q4 2024	AVTX Avalo Therapeutics	-$1.07	N/A	N/A	N/A	N/A	N/A
5/8/2025	Q1 2025	EQ Equillium	-$0.23	N/A	N/A	N/A	N/A	N/A
3/27/2025	Q4 2024	EQ Equillium	-$0.22	-$0.16	+$0.06	-$0.16	N/A	$4.39 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ARTV Artiva Biotherapeutics	N/A	N/A	N/A	N/A	N/A
AVTX Avalo Therapeutics	N/A	N/A	N/A	N/A	N/A
EQ Equillium	N/A	N/A	N/A	N/A	N/A
ZIVO ZIVO Bioscience	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ARTV Artiva Biotherapeutics	N/A	11.33	11.33
AVTX Avalo Therapeutics	N/A	1.42	1.42
EQ Equillium	N/A	3.04	3.04
ZIVO ZIVO Bioscience	N/A	0.17	0.17

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ARTV Artiva Biotherapeutics	N/A
AVTX Avalo Therapeutics	87.06%
EQ Equillium	27.05%
ZIVO ZIVO Bioscience	12.83%

Insider Ownership

Company	Insider Ownership
ARTV Artiva Biotherapeutics	N/A
AVTX Avalo Therapeutics	0.25%
EQ Equillium	31.60%
ZIVO ZIVO Bioscience	21.50%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ARTV Artiva Biotherapeutics	81	24.36 million	N/A	N/A
AVTX Avalo Therapeutics	40	10.67 million	10.37 million	Not Optionable
EQ Equillium	40	35.72 million	24.70 million	Not Optionable
ZIVO ZIVO Bioscience	10	3.81 million	2.91 million	Not Optionable

EQ, ARTV, AVTX, and ZIVO Headlines

Recent News About These Companies

University of Delaware Study Identifies Optimal Formulation of ZIVO’s Active Ingredients for Further Testing to Mitigate Avian Influenza in Poultry

May 7 at 3:36 AM | finance.yahoo.com

University of Delaware Study Identifies Optimal Formulation of ZIVO's Active Ingredients for Further Testing to Mitigate Avian Influenza in Poultry

May 6 at 5:54 PM | businesswire.com

ZIVO Bioscience (NASDAQ:ZIVO) Stock Price Crosses Above 50-Day Moving Average - Should You Sell?

April 30, 2025 | marketbeat.com

ZIVO Bioscience Plans New Study with University of Delaware to Combat Avian Influenza in Poultry

February 6, 2025 | businesswire.com

Zivo Bioscience issues new shares, raises $1.5 million

January 28, 2025 | msn.com

Tuesday's Insider Activity: Top Buys and Sells in US Stocks Revealed

January 1, 2025 | investing.com

ZIVO Bioscience Reports Preliminary Efficacy of its Proprietary Active Ingredients in the Battle Against Avian Influenza

December 20, 2024 | businesswire.com

ZIVO Stock Earnings: Zivo Bioscience Reported Results for Q4 2023

March 18, 2024 | investorplace.com

Harmony Biosciences Holdings

March 4, 2024 | forbes.com

Regencell Bioscience Holdings Ltd RGC

February 1, 2024 | morningstar.com

ZIVO Bioscience Announces Uplisting to OTCQB Market

January 29, 2024 | finance.yahoo.com

Ideaya Biosciences

January 18, 2024 | forbes.com

Dare Bioscience Inc DARE

January 14, 2024 | morningstar.com

Zivo Bioscience Inc (ZIVO) USD0.001

November 11, 2023 | hl.co.uk

Zivo Bioscience (ZIVO) Price Target Increased by 500.00% to 36.72

November 2, 2023 | msn.com

Zivo Bioscience Inc ZIVO

November 1, 2023 | morningstar.com

ZIVO Bioscience Initiates 42-Day Validation Study with Immune-Modulating Product for the Prevention and Treatment of Coccidiosis in Broiler Chickens

October 30, 2023 | finance.yahoo.com

Zivo Bioscience Announces 1-for-6 Reverse Stock Split To Regain Compliance

October 26, 2023 | markets.businessinsider.com

Zivo Bioscience to effect reverse stock split to regain compliance with Nasdaq rules

October 26, 2023 | msn.com

Adam Zivo: Nazi veteran’s memoir lays bare the pitfalls of nationalism

October 5, 2023 | nationalpost.com

ZIVO Bioscience to Present at the Dawson James Small Cap Growth Conference

October 3, 2023 | finance.yahoo.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

Walgreens Comeback? Private Equity Circling for a Buyout
By Gabriel Osorio-Mazilli | April 13, 2025
View Walgreens Comeback? Private Equity Circling for a Buyout
Buffett's Top 5 Stock Holdings Ahead of Next 13F Filing
By Ryan Hasson | May 2, 2025
View Buffett's Top 5 Stock Holdings Ahead of Next 13F Filing
How to Invest in Micro-Cap Stocks Like a Pro
By Dan Schmidt | April 22, 2025
View How to Invest in Micro-Cap Stocks Like a Pro
American Express: Affluent Customers Don’t Leave Home Without It
By Jea Yu | April 26, 2025
View American Express: Affluent Customers Don’t Leave Home Without It
3 Stocks Just Announced Intentions to Buyback Near 10% of Shares
By Leo Miller | April 28, 2025
View 3 Stocks Just Announced Intentions to Buyback Near 10% of Shares

EQ, ARTV, AVTX, and ZIVO Company Descriptions

Artiva Biotherapeutics NASDAQ:ARTV

$2.08 +0.16 (+8.07%)

Closing price 03:59 PM Eastern

Extended Trading

$2.11 +0.03 (+1.64%)

As of 06:00 PM Eastern

Artiva Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing natural killer (NK) cell-based therapies for patients suffering from autoimmune diseases and cancers. The company's lead product candidate is AB-101, an off-the-shelf NK cell therapy for patients with autoimmune diseases and cancers, such as lupus nephritis, rheumatoid arthritis, pemphigus vulgaris, the anti-neutrophil cytoplasmic antibody-associated vasculitis subtypes granulomatosis with polyangiitis/microscopic polyangiitis, systemic lupus erythematosus, and B-cell-non-Hodgkin lymphoma. It also develops AB-201, an allogeneic anti- human epidermal growth factor receptor 2 chimeric antigen receptor (CAR)-NK cell product candidate; and AB-205, an allogeneic anti-CD5 CAR-NK cell product candidate. The company was incorporated in 2019 and is headquartered in San Diego, California.

Avalo Therapeutics NASDAQ:AVTX

$4.45 -0.33 (-6.90%)

Closing price 04:00 PM Eastern

Extended Trading

$4.36 -0.09 (-2.11%)

As of 07:04 PM Eastern

Avalo Therapeutics, Inc., a clinical stage biotechnology company, focuses on the development of therapies for the treatment of immune dysregulation in the Unites States. The company's drug candidates include AVTX-009, an Anti-IL-1ß monoclonal antibody which is under Phase I targeting inflammatory diseases; and AVTX-008, a fully human B and T lymphocyte attenuator agonist fusion protein for the treatment of immune dysregulation disorders. It also develops Quisovalimab (AVTX-002), an Anti-LIGHT mAb which is in phase II for immune-inflammatory diseases. The company was formerly known as Cerecor Inc. and changed its name to Avalo Therapeutics, Inc. in August 2021. Avalo Therapeutics, Inc. was incorporated in 2011 and is headquartered in Rockville, Maryland.

Equillium NASDAQ:EQ

$0.39 +0.02 (+5.85%)

Closing price 03:52 PM Eastern

Extended Trading

$0.40 +0.01 (+3.57%)

As of 07:51 PM Eastern

Equillium, Inc., a clinical-stage biotechnology company, develops and sells products to treat severe autoimmune and inflammatory, or immuno-inflammatory disorders with unmet medical need. The company's lead product candidate is itolizumab (EQ001), a first-in-class monoclonal antibody that targets the immune checkpoint receptor CD6, which is in Phase III clinical trials for the treatment of acute graft-versus-host disease; completed Phase I clinical trial for the treatment of ulcerative colitis; and Phase I clinical trial for the treatment of lupus nephritis. It also develops EQ101 completed phase 1/2 for treatment of cutaneous T cell lymphoma and alopecia areata; and EQ302 to treat gastrointestinal indications. In addition, it serves dermatology, gastroenterology, rheumatology, hematology, transplant science, oncology, and pulmonology area. The company was formerly known as Attenuate Biopharmaceuticals, Inc. and changed its name to Equillium, Inc. in May 2017. Equillium, Inc. was incorporated in 2017 and is headquartered in La Jolla, California.

ZIVO Bioscience NASDAQ:ZIVO

$16.00 +2.21 (+16.03%)

As of 05/6/2025 01:39 PM Eastern

ZIVO Bioscience, Inc., a research and development company, engages in licensing and selling natural bioactive ingredients derived from its proprietary algae cultures to animal, human, and dietary supplement and medical food manufacturers. The company operates in the biotech and agtech sectors, with an intellectual property portfolio comprising proprietary algal and bacterial strains, biologically active molecules and complexes, production techniques, cultivation techniques, and patented or patent-pending inventions for applications in human and animal health. Its products indications include poultry gut health, bovine mastitis, canine joint health, human immune modification, algal biomass for human consumption, and biomass for supporting skin health / anti-aging. The company was formerly known as Health Enhancement Products, Inc. and changed its name to ZIVO Bioscience, Inc. in October 2014. ZIVO Bioscience, Inc. is headquartered in Bloomfield Hills, Michigan.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time